cagrisema cagrilintide semaglutide phase 3 obesity Novo's results disappoint analysts, sending stock tumbling - MM+M Cagrilintide and Semaglutide: CagriSema Weight
Description
Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity
Both its dual-agonist injectable poterepatide and its oral small molecule conveglipron are in Phase III, demonstrating significant late-stage momentum
Ozempic, Wegovy, Mounjaro, Zepbound what's the difference
Remedy Meds Subscription is a telehealth GLP-1 delivery platform offering branded and compounded options with monthly pricing models
Discover the future of weight management today and don't miss the opportunity to transform your health
